Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
IDEAYA Biosciences $92 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Alnylam Pharmaceuticals $1.035 billion convertible senior notes offering
The 1% convertible notes are due 2027
Immunocore $250 million at-the-market offering
The ADSs are listed on the Nasdaq Global Market
Novo Nordisk $1.1 billion acquisition of Forma Therapeutics
We are advising Novo Nordisk on the transaction
Biocytogen HK$549 million IPO
We advised Biocytogen on its IPO and HKEX listing
Blackstone and CPPIB $1.96 billion Advarra acquisition financing
We advised the lead arrangers and initial term lenders on the financing
Assertio $70 million convertible senior notes offering
The 6.5% notes are due 2027
Freeman Spogli investment in EverVet
We advised Tailwind Capital and EverVet on the transaction
Esco Aster spinoff transactions
We are advising Esco Lifesciences on the spinoff
Oak Street Health $180.3 million secondary offering
We advised the joint book-running managers on the equity offering